Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
0.4742
-0.0238 (-4.78%)
At close: Nov 13, 2026, 4:00 PM EST
0.4771
+0.0029 (0.61%)
After-hours: Nov 13, 2026, 7:49 PM EST
Akebia Therapeutics Revenue
Akebia Therapeutics had revenue of $36.90M in the quarter ending September 30, 2026, a decrease of -37.20%. This brings the company's total for the last twelve months to $197.20M, down -12.38% year-over-year. In the year 2025, Akebia Therapeutics had annual revenue of $236.20M with 47.46% growth. That makes Akebia Therapeutics the 17,589th largest company in the world by revenue and 2,888th in the United States.
Revenue (ttm)
$197.20M
Revenue Growth
-12.38%
P/S Ratio
0.66
Revenue / Employee
$1,016,479
Employees
194
Market Cap
131.67M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 236.20M | 76.02M | 47.46% |
| Dec 31, 2024 | 160.18M | -34.44M | -17.70% |
| Dec 31, 2023 | 194.62M | -97.86M | -33.46% |
| Dec 31, 2022 | 292.48M | 80.83M | 38.19% |
| Dec 31, 2021 | 211.65M | -82.99M | -28.17% |
| Dec 31, 2020 | 294.64M | -40.36M | -12.05% |
| Dec 31, 2019 | 335.00M | 127.26M | 61.26% |
| Dec 31, 2018 | 207.74M | 26.52M | 14.63% |
| Dec 31, 2017 | 181.23M | 179.69M | 11,706.32% |
| Dec 31, 2016 | 1.54M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Organogenesis Holdings | 352.05M |
| Organigram Global | 217.71M |
| Canopy Growth | 217.18M |
| Glass House Brands | 176.98M |
| Anika Therapeutics | 123.43M |
| Lifecore Biomedical | 106.46M |
| ADC Therapeutics | 84.87M |
| Journey Medical | 68.18M |
AKBA News
- 7 days ago - Akebia price target lowered to $4 from $6 at H.C. Wainwright - TheFly
- 8 days ago - Akebia price target lowered to $3 from $4 at BTIG - TheFly
- 8 days ago - Akebia reports topline results from VOCAL trial - TheFly
- 8 days ago - Akebia Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 8 days ago - Akebia Therapeutics Earnings release: Q3 2026 - Filings
- 8 days ago - Akebia Therapeutics Quarterly report: Q3 2026 - Filings
- 8 days ago - Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights - GlobeNewsWire
- 8 days ago - Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin - GlobeNewsWire